NCT06556342View on ClinicalTrials.gov

The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women

NARecruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2028

Study Completion Date

July 1, 2028

Conditions
Ovary Cancer
Interventions
DRUG

FRD001

FRD001 injection is a lipid-based second-generation ultrasound contrast agent. FRD001 injection in ultrasound contrast imaging could enhance the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls.

Trial Locations (1)

430030

RECRUITING

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
collaborator

Peking University People's Hospital

OTHER

lead

Tongji Hospital

OTHER